Coherus Oncology (CHRS) Other Accumulated Expenses (2013 - 2026)

Coherus Oncology (CHRS) has 14 years of Other Accumulated Expenses data on file, last reported at $10.9 million in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses fell 5.0% year-over-year to $10.9 million; the trailing twelve-month figure through Mar 2026 stood at $10.9 million (down 5.0% YoY), and the FY2025 full-year result was $11.3 million, down 43.81% from the prior year.
• Other Accumulated Expenses retreated to $10.9 million in Q1 2026, from $11.3 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $20.0 million in Q4 2024 to a low of $6.8 million in Q2 2025.
• A 5-year average of $12.0 million and a median of $11.4 million in 2025 frame the typical range for Other Accumulated Expenses.
• Across the five-year window, Other Accumulated Expenses jumped 204.52% in 2022 and tumbled 53.52% in 2025, its largest moves.
• Tracing CHRS's Other Accumulated Expenses over 5 years: stood at $10.6 million in 2022, then decreased by 28.27% to $7.6 million in 2023, then jumped by 162.56% to $20.0 million in 2024, then sank by 43.81% to $11.3 million in 2025, then dropped by 3.33% to $10.9 million in 2026.
• Business Quant data shows CHRS's Other Accumulated Expenses at $10.9 million in Q1 2026, $11.3 million in Q4 2025, and $7.1 million in Q3 2025.